Sonnet BioTherapeutics Analyst Ratings
Sonnet BioTherapeutics Analyst Ratings
While ratings are subjective and will change, the latest Sonnet BioTherapeutics (SONN) rating was a initiated with a price target of $0.00 to $6.70. The current price Sonnet BioTherapeutics (SONN) is trading at is $0.96, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 12/19/2022 | 595.74% | EF Hutton | → $6.7 | Initiates Coverage On | → Buy |
| 09/22/2022 | 2184.53% | Chardan Capital | $2 → $22 | Maintains | Buy |
| 08/16/2022 | 107.68% | Chardan Capital | $2.5 → $2 | Maintains | Buy |
| 02/09/2022 | 107.68% | BTIG | $5 → $2 | Maintains | Buy |
| 12/20/2021 | 159.61% | Chardan Capital | $8 → $2.5 | Maintains | Buy |
| 12/16/2021 | 107.68% | HC Wainwright & Co. | → $2 | Initiates Coverage On | → Buy |
| 09/15/2021 | 419.21% | BTIG | → $5 | Initiates Coverage On | → Buy |
| 09/04/2020 | 730.74% | Chardan Capital | $7 → $8 | Maintains | Buy |
| 06/05/2020 | 626.9% | Chardan Capital | → $7 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 12/19/2022 | 595.74% | EF Hutton | → $6.7 | 开始承保 | →购买 |
| 09/22/2022 | 2184.53% | 查尔丹资本 | $2 → $22 | 维护 | 买 |
| 08/16/2022 | 107.68% | 查尔丹资本 | $2.5 → $2 | 维护 | 买 |
| 02/09/2022 | 107.68% | BTIG | $5 → $2 | 维护 | 买 |
| 12/20/2021 | 159.61% | 查尔丹资本 | $8 → $2.5 | 维护 | 买 |
| 12/16/2021 | 107.68% | HC Wainwright公司 | → $2 | 开始承保 | →购买 |
| 09/15/2021 | 419.21% | BTIG | → $5 | 开始承保 | →购买 |
| 09/04/2020 | 730.74% | 查尔丹资本 | $7 → $8 | 维护 | 买 |
| 06/05/2020 | 626.9% | 查尔丹资本 | → $7 | 开始承保 | →购买 |
What is the target price for Sonnet BioTherapeutics (SONN)?
Sonnet BioTreateutics(SONN)的目标价格是多少？
The latest price target for Sonnet BioTherapeutics (NASDAQ: SONN) was reported by EF Hutton on December 19, 2022. The analyst firm set a price target for $6.70 expecting SONN to rise to within 12 months (a possible 595.74% upside). 5 analyst firms have reported ratings in the last year.
EF Hutton于2022年12月19日报道了十四网生物治疗公司(纳斯达克：SONN)的最新目标价。这家分析公司将目标价定为6.7美元，预计SUNN将在12个月内上涨(涨幅可能为595.74)。去年有5家分析公司公布了评级。
What is the most recent analyst rating for Sonnet BioTherapeutics (SONN)?
Sonnet BioTreateutics(SONN)的最新分析师评级是多少？
The latest analyst rating for Sonnet BioTherapeutics (NASDAQ: SONN) was provided by EF Hutton, and Sonnet BioTherapeutics initiated their buy rating.
十四Net生物治疗公司(纳斯达克代码：SONN)的最新分析师评级由EF Hutton提供，Sonnet生物治疗公司启动了他们的买入评级。
When is the next analyst rating going to be posted or updated for Sonnet BioTherapeutics (SONN)?
Sonnet BioTreeutics(SONN)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sonnet BioTherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sonnet BioTherapeutics was filed on December 19, 2022 so you should expect the next rating to be made available sometime around December 19, 2023.
分析师在进行了广泛的研究后得出股票评级，其中包括查阅公共财务报表，与Sonnet BioTreateutics的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Sonnet BioTreateutics的上一次评级是在2022年12月19日提交的，所以你应该预计下一次评级将在2023年12月19日左右提供。
Is the Analyst Rating Sonnet BioTherapeutics (SONN) correct?
分析师对Sonnet BioTreateutics(SONN)的评级正确吗？
While ratings are subjective and will change, the latest Sonnet BioTherapeutics (SONN) rating was a initiated with a price target of $0.00 to $6.70. The current price Sonnet BioTherapeutics (SONN) is trading at is $0.96, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Sonnet BioTreateutics(SONN)评级是以0.00美元至6.70美元的目标价启动的。目前Sonnet BioTreateutics(SUNN)的交易价格为0.96美元，在分析师的预测范围内。
